Radiation dosimetry of ¹⁸F-AzaFol: A first in-human use of a folate receptor PET tracer.

ABSTRACT:

Background

The folate receptor alpha (FRα) is an interesting target for imaging and therapy of different cancers. We present the first in-human radiation dosimetry and radiation safety results acquired within a prospective, multicentric trial (NCT03242993) evaluating the ¹⁸F-AzaFol (3'-aza-2'-[¹⁸F]fluorofolic acid) as the first clinically assessed PET tracer targeting the FRα.

Material and methods

Six eligible patients presented a histologically confirmed adenocarcinoma of the lung with measurable lesions (≥ 10 mm according to RECIST 1.1). TOF-PET images were acquired at 3, 11, 18, 30, 40, 50, and 60 min after the intravenous injection of 327 MBq (range 299-399 MBq) of ¹⁸F-AzaFol to establish dosimetry. Organ absorbed doses (AD), tumor AD, an

SUBMITTER: Gnesin S 

PROVIDER: S-EPMC7142191 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature